Using magnesium sulfate to reduce pain in prostate surgery
A Randomized, Controlled Trial of Magnesium Sulfate as an Adjunctive Analgesic in Prostate Surgery
This study is testing if magnesium sulfate can help reduce pain and improve recovery for people undergoing prostate surgery.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 110 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | NYU Langone Health Academic / other |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT06477133 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of magnesium sulfate as an adjunctive analgesic during prostate surgery. Participants will be randomly assigned to receive either magnesium sulfate or a placebo as part of their general anesthesia. The primary goal is to assess whether magnesium sulfate can lower pain scores post-surgery, while secondary objectives include evaluating the reduction of opioid use, postoperative shivering, and the effectiveness of neuromuscular blockade reversal. The study aims to enhance patient recovery and comfort during and after robotic prostatectomy.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who are scheduled for robotic prostatectomy under general anesthesia.
Not a fit: Patients with end-stage renal disease or known allergies to magnesium sulfate will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved pain management and reduced opioid consumption for patients undergoing prostate surgery.
How similar studies have performed: Other studies have shown promising results with magnesium sulfate in pain management, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18 and older. 2. Undergoing a robotic prostatectomy under general anesthesia. 3. Is willing and able to provide consent to participate in the study. Exclusion Criteria: 1. Patients younger than 18 years 2. Patients with end-stage renal disease 3. Known allergy to magnesium sulfate preparations 4. Any patient that the investigators feel cannot comply with all study related procedures
Where this trial is running
New York, New York
- NYU Langone Health — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Mark E. Nunnally, MD — NYU Langone Health
- Study coordinator: Mark Nunnally, MD
- Email: nunnally@nyulangone.org
- Phone: 212-263-2087
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.